Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 781 to 792 of 792 entries
Sorted by: Best Match Show Resources per page
Acromegaly with empty sella syndrome.

Endocrinology, diabetes & metabolism case reports

Daya R, Seedat F, Purbhoo K, Bulbulia S, Bayat Z.
PMID: 34253687
Endocrinol Diabetes Metab Case Rep. 2021 Jul 01;2021. doi: 10.1530/EDM-21-0049. Epub 2021 Jul 01.

SUMMARY: Acromegaly is a rare, chronic progressive disorder with characteristic clinical features caused by persistent hypersecretion of growth hormone (GH), mostly from a pituitary adenoma (95%). Occasionally, ectopic production of GH or growth hormone-releasing hormone (GHRH) with resultant GH...

Cite
Daya R, Seedat F, Purbhoo K, et al. Acromegaly with empty sella syndrome. Endocrinol Diabetes Metab Case Rep. 2021;2021doi: 10.1530/EDM-21-0049.
Daya, R., Seedat, F., Purbhoo, K., Bulbulia, S., & Bayat, Z. (2021). Acromegaly with empty sella syndrome. Endocrinology, diabetes & metabolism case reports, 2021. https://doi.org/10.1530/EDM-21-0049
Daya, Reyna, et al. "Acromegaly with empty sella syndrome." Endocrinology, diabetes & metabolism case reports vol. 2021 (2021). doi: https://doi.org/10.1530/EDM-21-0049
Daya R, Seedat F, Purbhoo K, Bulbulia S, Bayat Z. Acromegaly with empty sella syndrome. Endocrinol Diabetes Metab Case Rep. 2021 Jul 01;2021. doi: 10.1530/EDM-21-0049. Epub 2021 Jul 01. PMID: 34253687; PMCID: PMC8284961.
Copy Download .nbib Format: NLM
The use of high dose octreotide in management of neonatal chylothorax: Review.

Journal of neonatal-perinatal medicine

Alhasoon MA.
PMID: 33843702
J Neonatal Perinatal Med. 2021;14(4):457-461. doi: 10.3233/NPM-200644.

BACKGROUND: Being a rare condition, the incidence of chylothorax among neonates is low, but the mortality rate is high. In a dire effort to reduce the risk of death, octreotide treatment is used to effectively treat acquired and congenital...

Cite
Alhasoon MA. The use of high dose octreotide in management of neonatal chylothorax: Review. J Neonatal Perinatal Med. 2021;14(4):457-461doi: 10.3233/NPM-200644.
Alhasoon, M. A. (2021). The use of high dose octreotide in management of neonatal chylothorax: Review. Journal of neonatal-perinatal medicine, 14(4), 457-461. https://doi.org/10.3233/NPM-200644
Alhasoon, M A. "The use of high dose octreotide in management of neonatal chylothorax: Review." Journal of neonatal-perinatal medicine vol. 14,4 (2021): 457-461. doi: https://doi.org/10.3233/NPM-200644
Alhasoon MA. The use of high dose octreotide in management of neonatal chylothorax: Review. J Neonatal Perinatal Med. 2021;14(4):457-461. doi: 10.3233/NPM-200644. PMID: 33843702.
Copy Download .nbib Format: NLM
Direct effects of octreotide on osteoblast cell proliferation and function.

Journal of endocrinological investigation

Vitali E, Palagano E, Schiavone ML, Mantovani G, Sobacchi C, Mazziotti G, Lania A.
PMID: 35020172
J Endocrinol Invest. 2022 Jan 12; doi: 10.1007/s40618-022-01740-7. Epub 2022 Jan 12.

PURPOSE: Octreotide (OCT) is a first-generation somatostatin analog (SSA) used in the treatment of acromegaly and neuroendocrine tumors (NETs). In both diseases, OCT interacts with somatostatin receptors 2 and 5 (SSTR2 and SSTR5), inhibiting hormone hypersecretion and cell proliferation....

Cite
Vitali E, Palagano E, Schiavone ML, et al. Direct effects of octreotide on osteoblast cell proliferation and function. J Endocrinol Invest. 2022;doi: 10.1007/s40618-022-01740-7.
Vitali, E., Palagano, E., Schiavone, M. L., Mantovani, G., Sobacchi, C., Mazziotti, G., & Lania, A. (2022). Direct effects of octreotide on osteoblast cell proliferation and function. Journal of endocrinological investigation, . https://doi.org/10.1007/s40618-022-01740-7
Vitali, E, et al. "Direct effects of octreotide on osteoblast cell proliferation and function." Journal of endocrinological investigation vol. (2022). doi: https://doi.org/10.1007/s40618-022-01740-7
Vitali E, Palagano E, Schiavone ML, Mantovani G, Sobacchi C, Mazziotti G, Lania A. Direct effects of octreotide on osteoblast cell proliferation and function. J Endocrinol Invest. 2022 Jan 12; doi: 10.1007/s40618-022-01740-7. Epub 2022 Jan 12. PMID: 35020172.
Copy Download .nbib Format: NLM
Staged Management of Congenital Chylothorax With Hydrops Fetalis: An Insight Into EXIT Related Procedures.

Frontiers in pediatrics

Tai HL, Mok TYD, Chao AS, Chu SM, Lien R.
PMID: 33681104
Front Pediatr. 2021 Feb 17;9:633051. doi: 10.3389/fped.2021.633051. eCollection 2021.

No abstract available.

Cite
Tai HL, Mok TYD, Chao AS, et al. Staged Management of Congenital Chylothorax With Hydrops Fetalis: An Insight Into EXIT Related Procedures. Front Pediatr. 2021;9:633051doi: 10.3389/fped.2021.633051.
Tai, H. L., Mok, T. Y. D., Chao, A. S., Chu, S. M., & Lien, R. (2021). Staged Management of Congenital Chylothorax With Hydrops Fetalis: An Insight Into EXIT Related Procedures. Frontiers in pediatrics, 9633051. https://doi.org/10.3389/fped.2021.633051
Tai, Hung-Lin, et al. "Staged Management of Congenital Chylothorax With Hydrops Fetalis: An Insight Into EXIT Related Procedures." Frontiers in pediatrics vol. 9 (2021): 633051. doi: https://doi.org/10.3389/fped.2021.633051
Tai HL, Mok TYD, Chao AS, Chu SM, Lien R. Staged Management of Congenital Chylothorax With Hydrops Fetalis: An Insight Into EXIT Related Procedures. Front Pediatr. 2021 Feb 17;9:633051. doi: 10.3389/fped.2021.633051. eCollection 2021. PMID: 33681104; PMCID: PMC7925828.
Copy Download .nbib Format: NLM
Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience.

Indian pediatrics

Sharma R, Roy K, Satapathy AK, Kumar A, Nanda PM, Damle N, Houghton JAL, Flanagan SE, Radha V, Mohan V, Jain V.
PMID: 34992182
Indian Pediatr. 2022 Jan 05; Epub 2022 Jan 05.

BACKGROUND: There is limited data from India regarding medical management of congenital hyperinsulinism (CHI).OBJECTIVE: To study the molecular diagnosis, medical management and outcomes of children with CHI.STUDY DESIGN: Ambispective.PARTICIPANTS: Children with CHI admitted in from December, 2011 till March,...

Cite
Sharma R, Roy K, Satapathy AK, et al. Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience. Indian Pediatr. 2022;
Sharma, R., Roy, K., Satapathy, A. K., Kumar, A., Nanda, P. M., Damle, N., Houghton, J. A. L., Flanagan, S. E., Radha, V., Mohan, V., & Jain, V. (2022). Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience. Indian pediatrics, .
Sharma, Rajni, et al. "Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience." Indian pediatrics vol. (2022).
Sharma R, Roy K, Satapathy AK, Kumar A, Nanda PM, Damle N, Houghton JAL, Flanagan SE, Radha V, Mohan V, Jain V. Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience. Indian Pediatr. 2022 Jan 05; Epub 2022 Jan 05. PMID: 34992182.
Copy Download .nbib Format: NLM
Chyle leak occurring after vagal nerve stimulator implantation in a child.

Clinical neurology and neurosurgery

Winslow N, Pulido S, Garst J, Maldonado A.
PMID: 34959108
Clin Neurol Neurosurg. 2021 Dec 23;213:107104. doi: 10.1016/j.clineuro.2021.107104. Epub 2021 Dec 23.

Vagus nerve stimulation is a therapy indicated for some patients with medically-refractory epilepsy. Typical risks of this procedure include infection, hoarseness, vocal cord dysfunction, and hardware malfunction. Chyle leak via injury to the thoracic duct is a known complication...

Cite
Winslow N, Pulido S, Garst J, et al. Chyle leak occurring after vagal nerve stimulator implantation in a child. Clin Neurol Neurosurg. 2021;213:107104doi: 10.1016/j.clineuro.2021.107104.
Winslow, N., Pulido, S., Garst, J., & Maldonado, A. (2021). Chyle leak occurring after vagal nerve stimulator implantation in a child. Clinical neurology and neurosurgery, 213107104. https://doi.org/10.1016/j.clineuro.2021.107104
Winslow, Nolan, et al. "Chyle leak occurring after vagal nerve stimulator implantation in a child." Clinical neurology and neurosurgery vol. 213 (2021): 107104. doi: https://doi.org/10.1016/j.clineuro.2021.107104
Winslow N, Pulido S, Garst J, Maldonado A. Chyle leak occurring after vagal nerve stimulator implantation in a child. Clin Neurol Neurosurg. 2021 Dec 23;213:107104. doi: 10.1016/j.clineuro.2021.107104. Epub 2021 Dec 23. PMID: 34959108.
Copy Download .nbib Format: NLM
Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases.

The neurologist

Smyth D, Mossman S.
PMID: 34842577
Neurologist. 2021 Nov 26; doi: 10.1097/NRL.0000000000000368. Epub 2021 Nov 26.

INTRODUCTION: Bilateral vestibular failure (BVF) is an uncommon condition with numerous etiologies. It causes chronic oscillopsia and imbalance and is usually irreversible. We report 2 cases of BVF due to unusual causes, both of which improved with treatment of...

Cite
Smyth D, Mossman S. Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases. Neurologist. 2021;doi: 10.1097/NRL.0000000000000368.
Smyth, D., & Mossman, S. (2021). Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases. The neurologist, . https://doi.org/10.1097/NRL.0000000000000368
Smyth, Duncan, and Mossman, Stuart. "Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases." The neurologist vol. (2021). doi: https://doi.org/10.1097/NRL.0000000000000368
Smyth D, Mossman S. Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases. Neurologist. 2021 Nov 26; doi: 10.1097/NRL.0000000000000368. Epub 2021 Nov 26. PMID: 34842577.
Copy Download .nbib Format: NLM
Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review.

Frontiers in endocrinology

Chang SC, Tsai CY, Liu KH, Wang SY, Hsu JT, Yeh TS, Yeh CN.
PMID: 33868173
Front Endocrinol (Lausanne). 2021 Apr 01;12:639967. doi: 10.3389/fendo.2021.639967. eCollection 2021.

BACKGROUND: Everolimus, an immunosuppressant, is approved for the treatment of advanced renal cell carcinoma, metastatic hormone receptor-positive breast cancer, and pancreatic neuroendocrine tumors (P-NETs) but has been reported to be related to hepatitis B reactivation. Here, we present the...

Cite
Chang SC, Tsai CY, Liu KH, et al. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2021;12:639967doi: 10.3389/fendo.2021.639967.
Chang, S. C., Tsai, C. Y., Liu, K. H., Wang, S. Y., Hsu, J. T., Yeh, T. S., & Yeh, C. N. (2021). Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. Frontiers in endocrinology, 12639967. https://doi.org/10.3389/fendo.2021.639967
Chang, Shih-Chun, et al. "Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review." Frontiers in endocrinology vol. 12 (2021): 639967. doi: https://doi.org/10.3389/fendo.2021.639967
Chang SC, Tsai CY, Liu KH, Wang SY, Hsu JT, Yeh TS, Yeh CN. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2021 Apr 01;12:639967. doi: 10.3389/fendo.2021.639967. eCollection 2021. PMID: 33868173; PMCID: PMC8047461.
Copy Download .nbib Format: NLM
Formulation strategies to improve the efficacy of intestinal permeation enhancers.

Advanced drug delivery reviews

Maher S, Brayden DJ.
PMID: 34418495
Adv Drug Deliv Rev. 2021 Oct;177:113925. doi: 10.1016/j.addr.2021.113925. Epub 2021 Aug 18.

The use of chemical permeation enhancers (PEs) is the most widely tested approach to improve oral absorption of low permeability active agents, as represented by peptides. Several hundred PEs increase intestinal permeability in preclinical bioassays, yet few have progressed...

Cite
Maher S, Brayden DJ. Formulation strategies to improve the efficacy of intestinal permeation enhancers. Adv Drug Deliv Rev. 2021;177:113925doi: 10.1016/j.addr.2021.113925.
Maher, S., & Brayden, D. J. (2021). Formulation strategies to improve the efficacy of intestinal permeation enhancers. Advanced drug delivery reviews, 177113925. https://doi.org/10.1016/j.addr.2021.113925
Maher, Sam, and Brayden, David J. "Formulation strategies to improve the efficacy of intestinal permeation enhancers." Advanced drug delivery reviews vol. 177 (2021): 113925. doi: https://doi.org/10.1016/j.addr.2021.113925
Maher S, Brayden DJ. Formulation strategies to improve the efficacy of intestinal permeation enhancers. Adv Drug Deliv Rev. 2021 Oct;177:113925. doi: 10.1016/j.addr.2021.113925. Epub 2021 Aug 18. PMID: 34418495.
Copy Download .nbib Format: NLM
[No title available]

Pharmaceutics

Uccelli L, Boschi A, Cittanti C, Martini P, Panareo S, Tonini E, Nieri A, Urso L, Caracciolo M, Lodi L, Carnevale A, Giganti M, Bartolomei M.
PMID: 34575538
Pharmaceutics. 2021 Sep 13;13(9). doi: 10.3390/pharmaceutics13091463.

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in...

Cite
Uccelli L, Boschi A, Cittanti C, et al. . Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091463.
Uccelli, L., Boschi, A., Cittanti, C., Martini, P., Panareo, S., Tonini, E., Nieri, A., Urso, L., Caracciolo, M., Lodi, L., Carnevale, A., Giganti, M., & Bartolomei, M. (2021). . Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091463
Uccelli, Licia, et al. "." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091463
Uccelli L, Boschi A, Cittanti C, Martini P, Panareo S, Tonini E, Nieri A, Urso L, Caracciolo M, Lodi L, Carnevale A, Giganti M, Bartolomei M. . Pharmaceutics. 2021 Sep 13;13(9). doi: 10.3390/pharmaceutics13091463. PMID: 34575538; PMCID: PMC8469896.
Copy Download .nbib Format: NLM
Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.

Nuclear medicine communications

Reilly C, Gemmell AJ, McLaughlin IM, Fleming R, Reed N, McIntosh D, Nicol A.
PMID: 33741866
Nucl Med Commun. 2021 Aug 01;42(8):935-939. doi: 10.1097/MNM.0000000000001416.

99mTc Ethylene diamine N,N'-diacetic acid hydrazinonicotinamide-conjugated Tyr3-octreotide (99mTc EDDA/HYNIC-TOC) single photon emission tomography/computed tomography (SPECT/CT) imaging of somatostatin receptors is used in the assessment of neuroendocrine tumours (NETs). The objective of this study was to characterise quantitative standardised uptake...

Cite
Reilly C, Gemmell AJ, McLaughlin IM, et al. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience. Nucl Med Commun. 2021;42(8):935-939doi: 10.1097/MNM.0000000000001416.
Reilly, C., Gemmell, A. J., McLaughlin, I. M., Fleming, R., Reed, N., McIntosh, D., & Nicol, A. (2021). Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience. Nuclear medicine communications, 42(8), 935-939. https://doi.org/10.1097/MNM.0000000000001416
Reilly, Caitlin, et al. "Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience." Nuclear medicine communications vol. 42,8 (2021): 935-939. doi: https://doi.org/10.1097/MNM.0000000000001416
Reilly C, Gemmell AJ, McLaughlin IM, Fleming R, Reed N, McIntosh D, Nicol A. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience. Nucl Med Commun. 2021 Aug 01;42(8):935-939. doi: 10.1097/MNM.0000000000001416. PMID: 33741866.
Copy Download .nbib Format: NLM
A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor.

Endocrinology, diabetes & metabolism case reports

Chunharojrith P, Pradniwat K, Kongmalai T.
PMID: 33847280
Endocrinol Diabetes Metab Case Rep. 2021 Apr 12;2021. doi: 10.1530/EDM-20-0076. Epub 2021 Apr 12.

SUMMARY: Ectopic adrenocorticotropic hormone (ACTH) secretion is responsible for 5-15% of Cushing's syndrome (CS). Neuroendocrine tumor (NET) is a common cause of ectopic ACTH syndrome (EAS). However, primary renal NET is exceedingly rare. Fewer than 100 cases have been...

Cite
Chunharojrith P, Pradniwat K, Kongmalai T. A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor. Endocrinol Diabetes Metab Case Rep. 2021;2021doi: 10.1530/EDM-20-0076.
Chunharojrith, P., Pradniwat, K., & Kongmalai, T. (2021). A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor. Endocrinology, diabetes & metabolism case reports, 2021. https://doi.org/10.1530/EDM-20-0076
Chunharojrith, Paweena, et al. "A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor." Endocrinology, diabetes & metabolism case reports vol. 2021 (2021). doi: https://doi.org/10.1530/EDM-20-0076
Chunharojrith P, Pradniwat K, Kongmalai T. A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor. Endocrinol Diabetes Metab Case Rep. 2021 Apr 12;2021. doi: 10.1530/EDM-20-0076. Epub 2021 Apr 12. PMID: 33847280; PMCID: PMC8052562.
Copy Download .nbib Format: NLM
Showing 781 to 792 of 792 entries